Indication and Limitations of Use

Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.
Sensipar® is not indicated for use in adult patients with CKD who are not on dialysis because of an increased risk of hypocalcemia.

Important Safety Information

  • Sensipar® (cinacalcet) treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).
  • Sensipar® lowers serum calcium; therefore, it is important that patients are carefully monitored for the occurrence of hypocalcemia. Life threatening events and fatal outcomes associated with hypocalcemia have been reported in patients treated with Sensipar®, including pediatric patients.
  • Decreases in serum calcium can prolong the QT interval, potentially resulting in ventricular arrhythmia. Cases of QT prolongation and ventricular arrhythmia secondary to hypocalcemia have been reported in patients treated with Sensipar®.
  • Significant reductions in calcium may lower the threshold for seizures. Patients, particularly those with a history of seizure disorder, should be carefully monitored for the occurrence of low serum calcium or symptoms of hypocalcemia.
  • In Sensipar® postmarketing use, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia were reported in patients with impaired cardiac function. The causal relationship to Sensipar® therapy could not be completely excluded and may be mediated by reductions in serum calcium levels.
  • Cases of gastrointestinal (GI) bleeding, mostly upper GI bleeding, have occurred in patients using calcimimetics, including Sensipar, from postmarketing and clinical trial sources. The exact cause of GI bleeding in these patients is unknown.  
  • Patients with risk factors for upper GI bleeding, such as known gastritis, esophagitis, ulcers or severe vomiting, may be at increased risk for GI bleeding with Sensipar. Monitor patients for worsening of common Sensipar® GI adverse reactions and for signs and symptoms of GI bleeding and ulcerations during Sensipar therapy.
  • Adynamic bone disease may develop if intact parathyroid hormone (iPTH) levels are suppressed below 100 pg/mL.
  • Patients with moderate to severe hepatic impairment should be monitored throughout treatment with Sensipar®, as cinacalcet exposure assessed by area under the curve (AUC) was higher than in patients with normal hepatic function.
  • Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar®. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and PTH every 1 to 3 months.
  • In clinical trials of patients with secondary HPT comparing Sensipar® to placebo, the most commonly reported side effects were nausea (31% vs. 19%), vomiting (27% vs. 15%), and diarrhea (21% vs. 20%).

Indication
Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.

Limitations of Use:
Sensipar® is not indicated for use in adult patients with CKD who are not on dialysis because of an increased risk of hypocalcemia.

Please see Full Prescribing Information

References: 1. Sensipar® (cinacalcet) prescribing information, Amgen. 2. Goodman WG. Calcium and phosphorus metabolism in patients who have chronic kidney disease. Med Clin N Am. 2005;89:631-647. 3. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148-157. 4. Wesseling-Perry K, Harkins GC, Wang H, et al. The calcemic response to continuous parathyroid hormone (PTH) (1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH (7-84). J Clin Endocrinol Metab. 2010;95:2772-2780. 5. Komaba H, Shiizaki K, Fukagawa M. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges. Expert Opin Biol Ther. 2010;10:1729-1742. 6. Goodman WG, Quarles LD. Vitamin D, calcimimetics, and phosphate-binders: phosphate binding agents. In: Brenner BM, Levine SA, eds. Brenner & Rector’s The Kidney. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1919-1921. 7. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446-456. 8. Data on file, Amgen; [ESRD Dialysis Patient Chart Audit; Q2 2014]. 9. Data on file, Amgen; [Cinacalcet Integrated Analyses of Efficacy; 2003]. 10. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36-45. 11. Ureña-Torres P, Bridges I, Christiano C, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013;28:1241-1254. 12. Data on file, Amgen; [Clinical Study Report 20070360–Incident Dialysis Study; June 27, 2012]. 13. Data on file, Amgen; [Pooled phase 3 PTH and calcium reductions by baseline calcium analysis; November 2012]. 14. Food and Drug Administration Center for Drug Evaluation and Research. Clinical review for NDA 21-688 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm. Accessed June 21, 2015. 15. Brunelli SM, Dluzniewski P, Cooper K, Do T, Sibbel S, Bradbury BD. Serum calcium reductions among patients on hemodialysis initiating cinacalcet. Poster presented at: The American Society of Nephrology Renal Week; November 11-16, 2014; Philadelphia, PA. 16. Data on file, Amgen; [Pooled phase 3 concurrent achievement of PTH and serum phosphorus targets during the efficacy assessment phase; November 2014]. 17. Data on file, Amgen; [Cinacalcet New to Brand Patient Persistency; 2008-2014]. 18. Centers for Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2016 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. April 2015. Available at: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Announcements-and-Documents-Items/2016Announcement.html. Accessed January 12, 2016. 19. Centers for Medicare & Medicaid Services. Medicare Program; End–Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule. Fed Regist. 2014;79:66210-66265. Codified at 42 CFR Parts 405, 411, 413, and 414.